Malaysian Genomics Resource (0155) - Net Assets
Based on the latest financial reports, Malaysian Genomics Resource (0155) has net assets worth RM18.28 Million MYR (≈ $4.59 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RM21.40 Million ≈ $5.37 Million USD) and total liabilities (RM3.12 Million ≈ $782.07K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is Malaysian Genomics Resource's balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RM18.28 Million |
| % of Total Assets | 85.44% |
| Annual Growth Rate | -1.6% |
| 5-Year Change | -60.09% |
| 10-Year Change | -39.17% |
| Growth Volatility | 43.79 |
Malaysian Genomics Resource - Net Assets Trend (2015–2026)
This chart illustrates how Malaysian Genomics Resource's net assets have evolved over time, based on quarterly financial data. Check how tangible is Malaysian Genomics Resource's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Malaysian Genomics Resource (2015–2026)
The table below shows the annual net assets of Malaysian Genomics Resource from 2015 to 2026. For live valuation and market cap data, see how much is Malaysian Genomics Resource worth.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | RM14.78 Million ≈ $3.71 Million |
-18.57% |
| 2025-06-30 | RM18.16 Million ≈ $4.56 Million |
-18.76% |
| 2024-06-30 | RM22.35 Million ≈ $5.61 Million |
-16.58% |
| 2023-06-30 | RM26.79 Million ≈ $6.73 Million |
-27.69% |
| 2022-06-30 | RM37.05 Million ≈ $9.30 Million |
+106.62% |
| 2021-06-30 | RM17.93 Million ≈ $4.50 Million |
+74.79% |
| 2020-06-30 | RM10.26 Million ≈ $2.58 Million |
-35.61% |
| 2019-06-30 | RM15.93 Million ≈ $4.00 Million |
-19.42% |
| 2018-06-30 | RM19.77 Million ≈ $4.96 Million |
-18.66% |
| 2017-06-30 | RM24.30 Million ≈ $6.10 Million |
+25.34% |
| 2016-06-30 | RM19.39 Million ≈ $4.87 Million |
+9.85% |
| 2015-06-30 | RM17.65 Million ≈ $4.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Malaysian Genomics Resource's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 316935500.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2026)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | RM17.44 Million | 110.53% |
| Total Equity | RM15.77 Million | 100.00% |
Malaysian Genomics Resource Competitors by Market Cap
The table below lists competitors of Malaysian Genomics Resource ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Patria Private Equity Trust
LSE:PPET
|
$11.19 Million |
|
Ainos Inc
NASDAQ:AIMD
|
$11.19 Million |
|
Star Diamond Corp
TO:DIAM
|
$11.20 Million |
|
INNEOVA Holdings Limited
NASDAQ:INEO
|
$11.21 Million |
|
M.P.Evans Group
LSE:MPE
|
$11.17 Million |
|
Hays plc
LSE:HAS
|
$11.17 Million |
|
Admiralty Resources NL
AU:ADY
|
$11.16 Million |
|
AirIQ Inc
V:IQ
|
$11.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Malaysian Genomics Resource's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 18,155,360 to 15,774,191, a change of -2,381,169 (-13.1%).
- Net loss of 2,381,172 reduced equity.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RM-2.38 Million | -15.1% |
| Other Changes | RM3.00 | +0.0% |
| Total Change | RM- | -13.12% |
Book Value vs Market Value Analysis
This analysis compares Malaysian Genomics Resource's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.43x to 2.57x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | RM0.21 | RM0.30 | x |
| 2017-06-30 | RM0.23 | RM0.30 | x |
| 2018-06-30 | RM0.19 | RM0.30 | x |
| 2019-06-30 | RM0.15 | RM0.30 | x |
| 2020-06-30 | RM0.10 | RM0.30 | x |
| 2021-06-30 | RM0.15 | RM0.30 | x |
| 2022-06-30 | RM0.30 | RM0.30 | x |
| 2023-06-30 | RM0.21 | RM0.30 | x |
| 2024-06-30 | RM0.16 | RM0.30 | x |
| 2025-06-30 | RM0.13 | RM0.30 | x |
| 2026-06-30 | RM0.11 | RM0.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Malaysian Genomics Resource utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.68%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.19x
- Recent ROE (-15.10%) is below the historical average (-3.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 20.53% | 26.07% | 0.64x | 1.23x | RM1.86 Million |
| 2016 | 8.97% | 16.67% | 0.49x | 1.11x | RM-200.32K |
| 2017 | 2.42% | 5.97% | 0.26x | 1.56x | RM-1.84 Million |
| 2018 | -22.94% | -17.34% | 0.64x | 2.07x | RM-6.51 Million |
| 2019 | -24.10% | -1356.55% | 0.01x | 2.32x | RM-5.43 Million |
| 2020 | 166.70% | 1797.48% | 0.09x | 1.08x | RM16.07 Million |
| 2021 | -23.94% | -240.70% | 0.08x | 1.27x | RM-6.09 Million |
| 2022 | 19.46% | 25.43% | 0.68x | 1.13x | RM3.51 Million |
| 2023 | -53.18% | -170.33% | 0.27x | 1.15x | RM-16.92 Million |
| 2024 | -96.28% | -167.30% | 0.50x | 1.15x | RM-23.75 Million |
| 2025 | -23.09% | -75.90% | 0.25x | 1.23x | RM-6.01 Million |
| 2026 | -15.10% | -29.68% | 0.43x | 1.19x | RM-3.96 Million |
Industry Comparison
This section compares Malaysian Genomics Resource's net assets metrics with peer companies in the Diagnostics & Research industry.
No peer company data available for comparison.
About Malaysian Genomics Resource
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia. The company offers genetic screening services that includes Dtect and Origene genetic testing solutions which provides individuals with insights into genetic predispositions related to health risks, wellness, and lifestyle traits. It al… Read more